Hangzhou Paqisi Pharmaceutical Technology

Hangzhou Paqisi Pharmaceutical Technology is a specialty pharmaceutical company based in Hangzhou, China, dedicated to the research and development of complex formulations and long-acting delivery systems. The company focuses on high-barrier generic and improved new drugs (505(b)(2) pathway) using proprietary microsphere and nanocrystal technology platforms. Their primary therapeutic focus includes central nervous system (CNS) disorders, such as schizophrenia, and long-acting analgesia for pain management. By optimizing drug release profiles, Paqisi seeks to enhance patient adherence and reduce the frequency of administration for chronic conditions. The firm has successfully secured venture capital funding to advance its pipeline into clinical stages.